Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2019 Feb 8

PMID 30730037

Citations 6

Authors

Yuichiro Ito

James Van Schyndle

Takuya Nishimura

Toshifumi Sugitani

Tomomi Kimura

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was to evaluate the characteristics of new users of sodium glucose co-transporter-2 inhibitors (SGLT2i) in comparison with those of new users of other oral antidiabetic drugs (OADs) using data retrieved from three administrative databases in Japan.

Methods: This study included adult patients from each database who started an OAD between 2014 and 2017. Outpatients who started SGLT2i therapy were included in the SGLT2i cohort. The remaining outpatients were grouped according to the OAD class of their earliest initial prescription after no use of the index OAD during the 6-month pre-index period. Diabetes-related complications were evaluated using the Diabetes Complication Severity Index.

Results: In total, 176,355 patients in the hospital-based administrative database (H-dataset), 98,361 in the pharmacy claims database (P-dataset) and 37,786 in the insurance claims database (I-dataset) were analyzed. In the H-dataset, SGLT2i users, compared with users of other OADs, tended to be younger (mean age at index: 57.7 vs. 60.3-69.2 years) and to have a higher prevalence of hypercholesterolemia (73.5 vs. 55.2-71.4%), a higher mean body weight (74.4 vs. 60.5-70.8 kg), a higher body mass index (27.6 vs. 23.5-26.4 kg/m) and a higher glycated hemoglobin level (8.4 vs. 7.4-8.1%). There were no distinct differences in the prevalence of complications between SGLT2i users and users of other OADs in the H-dataset. Similar trends were noted in the other datasets.

Conclusion: Patients initiating SGLT2i therapy differed in several characteristics from new users of other OADs. SGLT2i were prescribed more frequently to younger patients, those at increased cardiovascular risk or those with poorer glycemic control.

Funding: Astellas Pharma Inc., Tokyo, Japan.

Citing Articles

Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.

Takahashi H, Suganuma Y, Ohno T, Nishimura R Diabetol Int. 2022; 13(4):606-614.

PMID: 36117921 PMC: 9477997. DOI: 10.1007/s13340-022-00577-y.

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in....

Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y J Diabetes Investig. 2022; 13(7):1175-1189.

PMID: 35243799 PMC: 9248422. DOI: 10.1111/jdi.13785.

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).

Tobe K, Maegawa H, Nakamura I, Uno S Diabetol Int. 2021; 12(2):181-196.

PMID: 33786273 PMC: 7943685. DOI: 10.1007/s13340-020-00470-6.

Data resource profile: JMDC claims databases sourced from Medical Institutions.

Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T J Gen Fam Med. 2020; 21(6):211-218.

PMID: 33304714 PMC: 7689231. DOI: 10.1002/jgf2.367.

Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014-2017).

Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T Diabetes Ther. 2019; 10(6):2233-2249.

PMID: 31628595 PMC: 6848432. DOI: 10.1007/s13300-019-00710-2.

References

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y . Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014; 30(7):1245-55. DOI: 10.1185/03007995.2014.912983. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

Goda M, Yamakura T, Sasaki K, Tajima T, Ueno M . Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Curr Med Res Opin. 2017; 34(2):319-327. DOI: 10.1080/03007995.2017.1392293. View

Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T . Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014; 5(2):415-33. PMC: 4269643. DOI: 10.1007/s13300-014-0086-7. View

. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2015; 25(1):2-10. DOI: 10.1002/pds.3891. View

Chao E, Henry R . SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9(7):551-9. DOI: 10.1038/nrd3180. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Hankins M, Tsai K, Kim J, Hammar N . Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany. Diabetes Res Clin Pract. 2017; 125:29-38. DOI: 10.1016/j.diabres.2016.10.025. View

Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K . Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther. 2015; 32(4):306-18. DOI: 10.1007/s12325-015-0198-0. View

10.

Wilke T, Mueller S, Groth A, Fuchs A, Seitz L, Kienhofer J . Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015; 14:14. PMC: 4343042. DOI: 10.1186/s12933-015-0179-2. View

11.

Ikeda S, Takano Y, Cynshi O, Tanaka R, Christ A, Boerlin V . A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015; 17(10):984-93. DOI: 10.1111/dom.12538. View

12.

Guthrie R . Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgrad Med. 2013; 124(6):82-9. DOI: 10.3810/pgm.2012.11.2614. View

13.

Elixhauser A, Steiner C, Harris D, Coffey R . Comorbidity measures for use with administrative data. Med Care. 1998; 36(1):8-27. DOI: 10.1097/00005650-199801000-00004. View

14.

Laakso M, Kuusisto J . Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014; 10(5):293-302. DOI: 10.1038/nrendo.2014.29. View

15.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

16.

van Walraven C, Austin P, Jennings A, Quan H, Forster A . A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-33. DOI: 10.1097/MLR.0b013e31819432e5. View

17.

Kimura S, Sato T, Ikeda S, Noda M, Nakayama T . Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010; 20(5):413-9. PMC: 3900837. DOI: 10.2188/jea.je20090066. View

18.

Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S . Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother. 2017; 19(3):189-201. DOI: 10.1080/14656566.2017.1408792. View

19.

Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H . Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014; 15(11):1501-15. DOI: 10.1517/14656566.2014.935764. View

20.

Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A . Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2015; 6(4):443-53. PMC: 4511304. DOI: 10.1111/jdi.12316. View